L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites

Area of Science:

• Oncology
• Molecular Biology
• Computational Chemistry

Background:

• Acquired resistance to anaplastic lymphoma kinase (ALK) inhibitors poses a significant challenge in treating ALK-positive non-small-cell lung cancer (NSCLC).
• A novel mutation, L1198F, has been observed to paradoxically restore sensitivity to crizotinib, the initial FDA-approved drug for ALK-positive NSCLC.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying the resensitization of ALK-positive NSCLC to crizotinib caused by the L1198F mutation.
• To understand how this rare mutation influences inhibitor binding and ALK protein activity.

Main Methods:

• Molecular dynamics (MD) simulations were employed to investigate the structural and dynamic changes associated with the L1198F mutation in ALK.
• Analysis focused on alterations in the inhibitor-binding site and the protein's autoactivation mechanisms.

Main Results:

• The L1198F mutation induces conformational changes in the ALK inhibitor-binding site, affecting binding affinities for crizotinib and lorlatinib.
• Key amino acids, His1124 and Tyr1278, were identified as critical for ATP binding and phosphorylation, with the L1198F mutation impacting these processes.
• The mutation influences ALK autoactivation pathways.

Conclusions:

• The L1198F mutation's effect on ALK conformation and binding affinity provides crucial insights into overcoming acquired resistance in ALK-positive NSCLC.
• Findings support the rational design of next-generation inhibitors with improved efficacy and broader activity against resistant mutations.
• This research contributes to developing more effective cancer therapies.